Jobs
-
According to Asthmapolis, the company has raised $5 million in Series A financing from The Social+Capital Partnership (“Social Capital”) that it will use to “deliver new innovations and services for its comprehensive solution of sensors,… Read more . . .
-
According to Insmed Incorporated, the US FDA has granted orphan drug designation to its Arikace liposomal amikacin for inhalation for the treatment of non-tuberculous mycobacteria (NTM) infections. Insmed is also developing Arikace for the treatment… Read more . . .
-
Device design and manufacturing company Nypro plans to build a device manufacturing facility in Waterford, Ireland and, according to the company, will hire 200 workers to staff the new plant. Nypro’s capabilities include injection molding… Read more . . .
-
Actavis says that it will launch 0.25 mg and 0.5 mg vials of its generic budesonide inhalation suspension immediately after the United States District Court for the District of New Jersey ruled that the products… Read more . . .
-
The UK’s National Institute for Health and Care Excellence (NICE) has issued a final guidance recommending Novartis’s Tobi Podhaler tobramycin DPI and Forest Lab’s Colobreathe colistimethate sodium DPI for the treatment of P. aeruginosa lung… Read more . . .
-
Pharmaceutical micronization specialist Micron Technologies has been acquired by private equity firm Arlington Capital Partners. Micron, which is based in Malvern, PA and has a facility in Dartford, UK, provides micronization services for both development… Read more . . .
-
According to the EMA, its Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion regarding the Labazenit budesonide/salmeterol dry powder inhaler. Belgian pharmaceutical company Laboratoires SMB applied to market the product, which… Read more . . .
-
The FDA has approved Novartis’s TOBI Podhaler tobramycin inhalation powder for the treatment of P. aeruginosa lung infections in cystic fibrosis patients. The agency’s Anti-Infective Drugs Advisory Committee (AIDAC) voted in favor of approval of… Read more . . .
-
The Pulmonary-Allergy Drugs Advisory Committee (PADAC) meeting regarding Breo Ellipta originally scheduled for March 7, 2013 has been rescheduled for April 17, 2013, from 8 am to 5 pm. The meeting was rescheduled due to… Read more . . .
-
Inhalation experts from the Woolcock Institute of Medical Research and the University of Sydney have launched a new company called Pulmatix to provide analytical services ranging from evaluation of APIs and formulations in respiratory cells… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK